Slingshot members are tracking this event:
U.S. FDA Approves Two Supplemental Indications for Harvoni in Chronic Hepatitis C Patients With Advanced Liver Disease
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Feb 16, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Fda, Harvoni, Chronic Hepatits C, Liver Disease, Chronic Hepatitis C Virus, Liver Transplant, Ledipasvir, Sofosbuvir, Chronic Hepatitis C